Search research articles
Contact Us
Filters
Showing results (241-250 of 282) with videos related to
Page
of 29
Sort By:
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
April 17, 1999
Genetic alterations in ovarian borderline tumours and ovarian carcinomas
M Schuyer, S C Henzen-Logmans, M E van der Burg, et al.
Molecular & Cellular Proteomics : MCP
|
March 31, 2009
Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer
Arzu Umar, Hyuk Kang, Annemieke M Timmermans, et al.
European Radiology
|
July 12, 2015
Feasibility of measuring renal blood flow by phase-contrast magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease
E M Spithoven, E Meijer, C Borns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study
Maurice P H M Jansen, Anieta M Sieuwerts, Maxime P Look, et al.
British Journal of Cancer
|
June 12, 2014
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
M Kriege, A Hollestelle, A Jager, et al.
Bone Marrow Transplantation
|
June 18, 2013
Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT
P J A de Pagter, R Schuurman, L Keukens, et al.
Cancer Research
|
February 17, 2000
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
J A Foekens, H A Peters, M P Look, et al.
Clinical Pharmacokinetics
|
August 30, 2022
Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels
Tessa C C Jaspers, Charlotte E Meijer, Louis Jean Vleming, et al.
Breast Cancer Research and Treatment
|
March 23, 2010
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer
E A Reijm, M P H M Jansen, K Ruigrok-Ritstier, et al.
British Journal of Cancer
|
November 12, 2009
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer
T van Agthoven, A M Sieuwerts, J Veldscholte, et al.
Page
of 29
Search research articles
Search
Showing results (241-250 of 282) with videos related to
Sort By:
Page
of 29
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
April 17, 1999
Genetic alterations in ovarian borderline tumours and ovarian carcinomas
M Schuyer, S C Henzen-Logmans, M E van der Burg, et al.
Molecular & Cellular Proteomics : MCP
|
March 31, 2009
Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer
Arzu Umar, Hyuk Kang, Annemieke M Timmermans, et al.
European Radiology
|
July 12, 2015
Feasibility of measuring renal blood flow by phase-contrast magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease
E M Spithoven, E Meijer, C Borns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study
Maurice P H M Jansen, Anieta M Sieuwerts, Maxime P Look, et al.
British Journal of Cancer
|
June 12, 2014
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
M Kriege, A Hollestelle, A Jager, et al.
Bone Marrow Transplantation
|
June 18, 2013
Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT
P J A de Pagter, R Schuurman, L Keukens, et al.
Cancer Research
|
February 17, 2000
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
J A Foekens, H A Peters, M P Look, et al.
Clinical Pharmacokinetics
|
August 30, 2022
Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels
Tessa C C Jaspers, Charlotte E Meijer, Louis Jean Vleming, et al.
Breast Cancer Research and Treatment
|
March 23, 2010
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer
E A Reijm, M P H M Jansen, K Ruigrok-Ritstier, et al.
British Journal of Cancer
|
November 12, 2009
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer
T van Agthoven, A M Sieuwerts, J Veldscholte, et al.
Page
of 29